Abstracts tagged "Myositis"

Abstract Number: 1157 • ACR Convergence 2024
Reduced Statin Use in Patients with Autoimmune Myopathies and Systemic Lupus Erythematosus Compared to Rheumatoid Arthritis and Non-Inflammatory Diseases
Shane Cameron, Liam O'Neil, Annaliese Tisseverasinghe and Christine Peschken, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatic diseases such as autoimmune myopathy (AIM), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) confer an increased risk for atherosclerotic disease. The 3-hydroxy-3-methylglutaryl-coenzyme…
Abstract Number: 1645 • ACR Convergence 2024
Antisynthetase Autoantibodies Disrupt the Function of Their Target Aminoacyl-tRNA Synthetases in Muscle Cells
Maria Casal-Dominguez¹, Iago Pinal-Fernandez², Sandra Muñoz-braceras³, Corinna preuße⁴, katherine Pak¹, Jiram Torres Ruiz⁵, Jon Musai¹, Stefania Dell'Orso⁶, Faiza Naz⁶, Shamima Islam², Gusatavo Gutierrez-Cruz², Albert Selva-O’Callaghan⁷, jose milisenda⁸, Werner Stenzel⁹ and Andrew Mammen², ¹National Institutes of health, Bethesda, MD, ²NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵INCMNSZ, Mexico, Federal District, Mexico, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁷Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁸Hospital Clinic de Barcelona, Barcelona, Spain, ⁹Charite University, Berlin, Germany
Background/Purpose: Antisynthetase syndrome (AS) is type of myositis characterized by autoantibodies targeting aminoacyl-transfer tRNA synthetases (aaRSs), the enzymes responsible for loading the appropriate amino acid…
Abstract Number: 2071 • ACR Convergence 2024
Self-Efficacy Contributes to Better Health Outcomes in Patients of Idiopathic Inflammatory Myopathies: Insights from the COVAD 3 Dataset
praggya yaadav¹, Maria Rosa Pellico², Anne-Marie Russell³, Aviya Lanis⁴, Elena Nikiphorou⁵, Ioannis Parodis⁶, Sreoshy Saha⁷, Manali Sarkar⁸, Jasmine Parihar⁹, Laura Andreoli¹⁰, Vikas Agarwal¹¹ and Latika Gupta¹², and COVAD Steering Committee, COVAD Study Group, ¹Maharashtra Institute of Medical Sciences and Research, Latur, Aurangabad, India, ²University of Milan, Milan, Italy, ³Birmingham Regional Interstitial Lung Disease Service, University Hospitals Birmingham NHS Trust and Faculty of Life Sciences, University of Exeter, Exeter, UK, Birmingham, United Kingdom, ⁴Seattle Children's Hospital, Seattle, WA, ⁵King's College London, London, United Kingdom, ⁶Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ⁷Mymensingh Medical College, Mymensingh, Bangladesh, ⁸MGM Medical College, Navi Mumbai, Maharashtra, India, ⁹All India Institute of Medical Science, New Delhi, Delhi, India, ¹⁰University of Brescia, Brescia, Italy, ¹¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹²Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom
Background/Purpose: Self-efficacy is crucial for chronic disease management. Given the increasing prevalence of chronic diseases, encouraging patients to actively manage their disease may be an…
Abstract Number: 2406 • ACR Convergence 2024
Neuropsychiatric Manifestations in Indian SLE Inception Cohort for Research: Prevalence, Predictors and Outcomes
Sai Yasaswini Kommaraju¹, Liza Rajasekhar², Ashish J Mathew³, Vineeta Shobha⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Able Lawrence⁷, Bidyut Das⁸, Manish Rathi⁹, Ranjan Gupta¹⁰, Avinash Jain¹¹ and Amita Aggarwal¹², ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ²Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ³Christian Medical College, Vellore, Tamil Nadu, India, ⁴St. John’s Medical College, Bengaluru , India, Bangalore, India, ⁵Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ⁸SCB Medical College, Cuttack, Orissa, India, ⁹Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹⁰All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹¹Sawai Man Singh Hospital, Lucknow, Rajasthan, India, ¹²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) has a significant impact on morbidity associated with SLE. However, the prevalence of NPSLE has been reported variably based…
Abstract Number: 0329 • ACR Convergence 2024
Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical Trials: Future Steps for Equitable Representation by the MIHRA Global Equity and Clinical Trial Readiness Cores
Raisa Silva¹, Manuel Carpio Tumba², Sneha Gupta³, Latika Gupta⁴, Pedro M Machado⁵, Julie Paik⁶, Diana Louden⁷, Lesley Ann Saketkoo⁸, Sebastian E. Sattui² and Didem Saygin⁹, ¹Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center McKeesport, Pittsburgh, PA, ⁴Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom, ⁵Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Washington Libraries, Seattle, WA, ⁸New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ⁹Rush University Medical Center, Chicago, IL
Background/Purpose: The growing number of randomized clinical trials (RCTs) in idiopathic inflammatory myopathies (IIMs) points to a promising future for therapeutics in IIM. Adequate representation…
Abstract Number: 1079 • ACR Convergence 2024
Early Recognition of Myositis: Time Correlation Between Transaminases and Inflammatory Myopathy in a Community-Based Rheumatology Practice
Anjali nidhaan, Shannon Iriza, Abbie West, Michael martin and Gauri Pethe, prisma health, columbia, SC
Background/Purpose: Recognizing muscle breakdown as a potential cause of elevated transaminases is crucial in the primary care setting to facilitate early referral to rheumatology for…
Abstract Number: 1159 • ACR Convergence 2024
Anti-synthetase Syndrome (ASSD) Related Interstitial Lung Disease (ILD) in Comparison to Non-ASSD Related ILDs: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Sangmee Bae¹, Francisca Bozan², Daphne Rivero Gallegos³, Giovanni Zanframundo⁴, Sara Faghihi-Kashani⁵, iazsmin Ventura⁶, Eduardo Dourado⁷, Aravinthan Loganathan⁸, Gianluca sambataro⁹, Akira Yoshida¹⁰, Francesco Bonella¹¹, Tamera J Corte¹², Tracy J Doyle¹³, david fiorentino¹⁴, Miguel Angel Gonzalez-Gay¹⁵, marie Hudson¹⁶, Masataka Kuwana¹⁷, Antonella Notarnicola¹⁸, Andrew Mammen¹⁹, Neil McHugh²⁰, Frederick Miller²¹, Carlomaurizio Montecucco²², Chester Oddis²³, Jorge Rojas-Serrano²⁴, Jens Schmidt²⁵, Carlo Scire²⁶, Albert Selva-O’Callaghan²⁷, Victoria Werth²⁸, Lorenzo Cavagna²⁹ and Rohit Aggarwal³⁰, ¹UCLA, Los Angeles, CA, ²Hospital Clinico Universidad de Chile, Santiago, Chile, ³INER, Ciudad de México, Mexico State, Mexico, ⁴Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ⁶Section of Rheumatology, University of Chicago, Chicago, IL, ⁷Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, ⁸RUH, Middle Park, Queensland, Australia, ⁹University of Catania, Catania, Italy, ¹⁰Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ¹¹Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ¹²Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, ¹³Brigham and Women's Hospital, West Roxbury, MA, ¹⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ¹⁵University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁶McGill University, Montreal, QC, Canada, ¹⁷Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ¹⁹NIH, Bethesda, MD, ²⁰University of Bath, Bath, United Kingdom, ²¹NIH, NIEHS, Chapel Hill, NC, ²²IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²⁴National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, ²⁵University Medical Center Goettingen, Göttingen, Germany, ²⁶University of Milano Bicocca, Milan, Italy, ²⁷Internal Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain, ²⁸University of Pennsylvania, Wynnewood, PA, ²⁹University of Pavia, Pavia, Italy, ³⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Anti-synthetase syndrome (ASSD) is a subset of idiopathic inflammatory myopathy characterized by autoantibodies directed against aminoacyl tRNA synthetases. Interstitial lung disease (ILD) can be…
Abstract Number: 1729 • ACR Convergence 2024
Prophylaxis Against Pneumocystis Jerovecii Pneumonia for Patients with Systemic Autoimmune Diseases: Analysis of the Veterans Affairs Database
Karolina Lungova¹, Katherine Sherman², Mahum Mirza¹, Rohan Mehta¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Research Division, Zablocki Veterans Affairs, Milwaukee, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect immunocompromised patients. PJP prophylaxis has been recommended for some autoimmune diseases but not others.…
Abstract Number: 2072 • ACR Convergence 2024
Clinical and Laboratory Features Associated with Pulmonary Involvement in Patients with Inflamatory Myopathy
Sonja Praprotnik¹, Katja Perdan-Pikmajer², Katja Lakota³, Ziga Rotar⁴ and Alojzija Hocevar⁵, ¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ²University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ³UMC Ljubljana, Ljubljana, Slovenia, ⁴University Clinical Center, Ljubljana, Slovenia, ⁵University Medical Center Ljubljana, LJUBLJANA, Slovenia
Background/Purpose: Polymyositis (PM), dermatomyositis (DM), and anti-synthetase syndrome (AS) are conditions included among idiopathic inflammatory myopathies (IMs).. Interstitial lung disease (ILD) is one of the…
Abstract Number: 2664 • ACR Convergence 2024
BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease
Laura Bucci¹, Melanie Hagen², Sebastian Boeltz², Danae-Mona Noethling², Tobias Rothe², Maria Gabriella Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Aline Bozec¹, Georg Schett³ and Ricardo Grieshaber-Bouyer², ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Targeting B cells and plasma cells is a key therapeutic strategy in autoimmune disease(AID). Therapy with CD19-targeted chimeric antigen receptor (CAR) T-cells and bi-specific…
Abstract Number: 0169 • ACR Convergence 2023
Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective
Alejandro Figueroa-Lara¹, Mary Ann Aure² and Carmen Andalucia¹, ¹Werfen, San Diego, CA, ²Werfen, Chula Vista, CA
Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) is a subgroup of immune-mediated myopathies (IMM). The diagnosis of IMNM relied on the presence of proximal muscle weakness, high…
Abstract Number: 0304 • ACR Convergence 2023
Incidence of Disease Flares Following COVID-19 Vaccination in a Diverse Idiopathic Inflammatory Myopathy Cohort
Hillary Weisleder¹, Ana Valle¹, Xianhong Xie² and Shereen Mahmood³, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY
Background/Purpose: Autoimmune activation in the setting of vaccination against coronavirus disease 2019 (COVID-19) is a well-documented phenomenon in the medical literature. For patients with idiopathic…
Abstract Number: 1161 • ACR Convergence 2023
Proteasome Inhibitor Repurposed for Dermatomyositis: Results of a Drug Repurposing Analysis Based on the Transcriptomic Signature of Patients’ Perifascicular Fibers Validated in Pre-clinical Models
Léa Debrut¹, Margherita Giannini², Céline Keime¹, Daniela Rovito¹, Béatrice Lannes³, Anne-Laure Charles⁴, Daniel Metzger¹, Bernard Geny⁵, Gilles Laverny¹ and Alain Meyer⁶, ¹Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, France, ²Nouvel Hopital Civil, Strasbourg, Strasbourg, France, ³Hôpital de Hautepierre - Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁴UR3072, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Strasbourg, France, ⁵Nouvel Hôpital Civil, Strasbourg, France, ⁶Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Background/Purpose: Dermatomyositis (DM) is an autoimmune myopathy responsible for muscle weakness associated with decreased quality of life and increased mortality. DM muscular histology is characterized…
Abstract Number: 1246 • ACR Convergence 2023
Assessment and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis
Belina Yi¹, Dawn Wahezi², Lauren Covert³, Kaveh Ardalan⁴, Joyce Hui-Yuen⁵, Natalia Vasquez Canizares⁶, Doaa Mosad Mosa⁷, Madison Jones⁸, Colleen Correll⁹, Alexis Begezda¹⁰, Susan Shenoi¹¹, Eveline Wu¹², Leonard Kovalick¹³, William Lapin¹⁴, Stacey Tarvin¹⁵, Melissa Oliver¹⁶, Martha Rodriguez¹⁷, Itay Marmor¹⁸, Kevin Baszis¹⁹, Alysha Taxter²⁰, Andrew Hanson²¹, Cynthia Crowson²² and Amir Orandi²², ¹Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital at Montefiore, New Rochelle, NY, ³Duke University, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵North Shore LIJ Health System, Great Neck, NY, ⁶Children's Hospital at Montefiore, New York, NY, ⁷Mansoura University Hospitals, Mansoura University Faculty of Medicine, Mansoura city, Egypt, ⁸Keck School of Medicine of University of Southern California, Los Angeles, CA, ⁹University of Minnesota, Minneapolis, MN, ¹⁰Penn State, Hummelstown, PA, ¹¹Seattle Childrens Hospital, Mercer Island, WA, ¹²University of North Carolina School of Medicine, Chapel Hill, NC, ¹³UNC Health Care, Durham, NC, ¹⁴Connecticut Children's, Hartford, CT, ¹⁵Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ¹⁶Indiana University, Indianapolis, IN, ¹⁷Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ¹⁸Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ¹⁹Washington Univ in St. Louis School of Medicine, St. Louis, MO, ²⁰Nationwide Children's, Columbus, OH, ²¹Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ²²Mayo Clinic, Rochester, MN
Background/Purpose: Calcinosis is a poorly understood and morbid complication of juvenile dermatomyositis (JDM). As there is no consensus treatment approach for calcinosis, and limited knowledge…
Abstract Number: 1961 • ACR Convergence 2023
Anti-PM/Scl Autoantibodies in Juvenile Myositis Are Associated with a Distinct Phenotype Resembling Anti-synthetase Syndrome
Matthew Sherman¹, Payam Noroozi Farhad², Edward Trieu³, Katherine Pak⁴, Iago Pinal-Fernandez⁴, Kakali Sarkar², Megan Neely⁵, Ira Targoff⁶, Frederick Miller⁷, Andrew Mammen⁸ and Lisa Rider⁹, ¹NIAMS/NIH, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴National Institutes of Health, Bethesda, MD, ⁵Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, ⁶Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷NIH, NIEHS, Chapel Hill, NC, ⁸NIH, Bethesda, MD, ⁹NIEHS, NIH, Bethesda, MD
Background/Purpose: Anti-PM/Scl autoantibodies (Abs) are an uncommon myositis-associated autoantibody (MAA) in juvenile myositis. The clinical features and outcomes associated with anti-PM/Scl Abs in juvenile myositis…

« Previous Page
1
…
5
6
7
8
9
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].